Mechanisms and consequences of chemotherapy resistance in breast cancer

European Journal of Cancer, Supplement

Volumn 7, Issue 1, 2009, Pages 3-7

  Coley, Helen M ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Chemotherapy; Epothilones; MDR; Metastatic breast cancer; Resistance

Indexed keywords

ABC TRANSPORTER; ANTHRACYCLINE; AZACITIDINE; DNA TOPOISOMERASE INHIBITOR; EPOTHILONE B; EPOTHILONE DERIVATIVE; FOLIC ACID ANTAGONIST; GLYCOPROTEIN P; IXABEPILONE; LAPATINIB; MULTIDRUG RESISTANCE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NUCLEOSIDE ANALOG; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TUBULIN; VINCA ALKALOID;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SPECIFICITY; ENZYME ACTIVATION; FEMALE; HUMAN; METASTASIS; MISMATCH REPAIR; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RISK FACTOR; TREATMENT FAILURE; TREATMENT PLANNING; TUMOR CELL;

EID: 61349169676     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(09)70003-5     Document Type: Article

References (20)

1. Longley D.B., and Johnston P.G. Molecular mechanisms of drug resistance. J Pathol 205 (2005) 275-292
2. Scotto K.W. Transcriptional regulation of ABC drug transporters. Oncogene 22 (2003) 7496-7511
3. Michor F., Nowak M.A., and Iwasa Y. Evolution of resistance to cancer therapy. Curr Pharm Des 12 (2006) 261-271
4. Son B.H., Ahn S.H., Ko C.D., Ka I.W., Gong G.Y., and Kim J.C. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Breast J 10 (2004) 20-26
5. Osani M., Murata M., Chiba H., Kojima T., and Sawada N. Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells. Cancer Sci 98 (2007) 1557-1562
6. Higgins C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature 446 (2007) 749-757
7. Leonard G.D., Fojo T., and Bates S.E. The role of ABC transporters in clinical practice. Oncologist 8 (2003) 411-424
8. Trock B.J., Leonessa F., and Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89 (1997) 917-931
9. Rudas M., Filipits M., Taucher S., et al. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat 81 (2003) 149-157
10. Clarke R., Leonessa F., and Trock B. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol 32 6 Suppl 7 (2005) S9-S15
11. Hasegawa S., Miyoshi Y., Egawa C., et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 9 (2003) 2992-2997
12. Kavallaris M., Kuo D.Y., Burkhart C.A., et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100 (1997) 1282-1293
13. Coley H.M. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 34 (2008) 378-390
14. Burkhart C.A., Kavallaris M., and Band Horwitz S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471 (2001) O1-O9
15. McDaid H.M., Mani S., Shen H.J., Muggia F., Sonnichsen D., and Horwitz S.B. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 8 (2002) 2035-2043
16. Ajabnoor G.M., Macanas-Pirard P., Shotton C.F., et al. Paclitaxel-resistance MCF-7 cells show a caspase-less phenotype but retain sensitivity to many anticancer agents. Proc AACR 49 (2008) 3657
17. Thomas H., and Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10 (2003) 159-163
18. Modok S., Mellor H.R., and Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 6 (2006) 350-354
19. Lee F.Y., Borzilleri R., Fairchild C.R., et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7 (2001) 1429-1437
20. Lee F.Y., Wen M.-L., Shen H., et al. Ixabepilone overcomes multiple mechanisms of drug resistance including overexpression of class III b-tubulin and breast cancer resistance protein. EJC Suppl 6 (2008) 219-220